Latest Prothena Corporation Plc (PRTA) Headlines
Prothena Reports Fourth Quarter and Full Year 2013 Financial Results and Provides Research and Development Update
GlobeNewswire - Fri Mar 07, 2:59AM CST
Prothena Corporation plc (Nasdaq
RTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, today reported financial results for the fourth quarter and year ended December 31, 2013 and provided an update on research and development.
Quarterly and Annual Financial Results Release, Executive Appointments, Upcoming Conferences, and Promotion Announcements - Analyst Notes on NuVasive, IPC, Portola, ICU Medical, and Prothena
PR Newswire - Wed Mar 05, 7:32AM CST
Editor Note: For more information about this release, please scroll to bottom.
Prothena Announces Appointment of Chief Business Officer
Thomson Reuters ONE - Mon Mar 03, 3:05PM CST
DUBLIN, Ireland, March 3, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NasdaqRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, announced today the promotion of Tara Nickerson, PhD, MBA, to Chief Business Officer. Dr. Nickerson is responsible for leading corporate and business development, as well as alliance management efforts at Prothena. Prior to this appointment, Dr. Nickerson held the position of Head of Corporate and Business Development at Prothena, where she was instrumental during Prothena's demerger from Elan Corporation Limited (formerly Elan Corporation, plc) and led the team that developed Prothena's previously announced worldwide collaboration with Roche to develop and commercialize antibodies that target alpha-synuclein, including PRX002, Prothena's monoclonal antibody for the treatment of Parkinson's disease and other related synucleinopathies.
Court Grants N50 Million Bail to Two MTN Employees Accused of N1.3 Billion Theft
All Africa Global Media - Thu Feb 27, 1:05AM CST
An Ikeja High Court on Wednesday granted bail to two MTN employees, Victor Akintunde and Gani Mustapha, charged with stealing N1.3 billion belonging to the firm's cooperative society.
Prothena to Report Fourth Quarter and Full Year 2013 Financial Results and Host Webcast and Conference Call on March 6
Thomson Reuters ONE - Tue Feb 18, 3:05PM CST
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
Prothena Announces Closing of Underwritten Public Offering of Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional Ordinary Shares From Perrigo
Thomson Reuters ONE - Mon Feb 03, 3:05PM CST
DUBLIN, Ireland, Feb. 3, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NasdaqRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding and cell adhesion, announced today the closing of a previously announced underwritten public offering of its ordinary shares owned by Elan Science One Limited (the "Selling Shareholder"), an indirect wholly owned subsidiary of Perrigo Company plc ("Perrigo"). The offering of 3,182,253 ordinary shares of Prothena included 415,076 ordinary shares that were sold pursuant to the underwriters' option to purchase additional shares, which was exercised in full prior to closing. The ordinary shares were sold at a price to the public of $26.00 per ordinary share, before the underwriting discount. As a result of the full exercise of the underwriters' option, the Selling Shareholder and Perrigo no longer own any ordinary shares of Prothena.
3 Big-Volume Biotech Stocks to Watch
at The Street - Thu Jan 30, 6:00AM CST
Keep these biotech stocks rising on unusual volume on your radar.
3 Companies Working on Parkinson's Treatments You Ought to Know About
Todd Campbell, The Motley Fool - Motley Fool - Wed Jan 29, 1:52PM CST
Parkinson's Disease effects between 7 million and 10 million patients worldwide. Roughly 60,000 new cases will be diagnosed in the United States this year alone, yet despite that big unmet need drug makers have stumbled in their attempts to bring...
Prothena Announces Pricing of Secondary Offering of Ordinary Shares by Perrigo
Thomson Reuters ONE - Wed Jan 29, 7:01AM CST
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
Prothena Corporation plc proposes secondary offering of 2.77m ordinary shares
M2 - Tue Jan 28, 3:48AM CST
Biotechnology company Prothena Corporation plc (NasdaqGSRTA) said on Monday that it plans to offer an underwritten secondary public offering of 2,767,177 ordinary shares.
Prothena Announces Proposed Secondary Offering of Ordinary Shares by Perrigo
Thomson Reuters ONE - Mon Jan 27, 3:26PM CST
DUBLIN, Ireland, Jan. 27, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NasdaqRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding and cell adhesion, announced today the underwritten public offering of 2,767,177 ordinary shares of Prothena by Elan Science One Limited (the "Selling Shareholder"), an indirect wholly owned subsidiary of Perrigo Company plc ("Perrigo"). In addition, the Selling Shareholder has granted the underwriters a 30-day option to purchase up to an additional 415,076 ordinary shares.
Prothena to Receive $30 Million Upfront Payment from Roche Triggered by the Expiration of Hart-Scott-Rodino Waiting Period
Thomson Reuters ONE - Thu Jan 23, 7:00AM CST
DUBLIN, Ireland, Jan. 23, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NasdaqRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding and cell adhesion, announced today that, pursuant to its License, Development, and Commercialization Agreement with Roche, it will receive the $30 million upfront payment from Roche as a result of the License Agreement having become effective upon the expiration of the Hart-Scott-Rodino waiting period.
Prothena to be Added to NASDAQ Biotechnology Index and NASDAQ Global Select Market
Thomson Reuters ONE - Mon Dec 30, 7:00AM CST
DUBLIN, Ireland, Dec. 30, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NasdaqRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of a broad range of diseases, today announced that it was selected for addition to the NASDAQ Biotechnology Index (Nasdaq:NBI), which became effective before market open on December 23, 2013. Prothena also announced that its common stock will be transferred to the NASDAQ Global Select Market effective January 2, 2014.
Prothena Reports Fourth Quarter and Full Year 2013 Financial Results and Provides Research and Development Update
GlobeNewswire - Fri Mar 07, 2:59AM CST
Prothena Corporation plc (Nasdaq
RTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, today reported financial results for the fourth quarter and year ended December 31, 2013 and provided an update on research and development. Quarterly and Annual Financial Results Release, Executive Appointments, Upcoming Conferences, and Promotion Announcements - Analyst Notes on NuVasive, IPC, Portola, ICU Medical, and Prothena
PR Newswire - Wed Mar 05, 7:32AM CST
Editor Note: For more information about this release, please scroll to bottom.
Prothena Announces Appointment of Chief Business Officer
Thomson Reuters ONE - Mon Mar 03, 3:05PM CST
DUBLIN, Ireland, March 3, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq
RTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, announced today the promotion of Tara Nickerson, PhD, MBA, to Chief Business Officer. Dr. Nickerson is responsible for leading corporate and business development, as well as alliance management efforts at Prothena. Prior to this appointment, Dr. Nickerson held the position of Head of Corporate and Business Development at Prothena, where she was instrumental during Prothena's demerger from Elan Corporation Limited (formerly Elan Corporation, plc) and led the team that developed Prothena's previously announced worldwide collaboration with Roche to develop and commercialize antibodies that target alpha-synuclein, including PRX002, Prothena's monoclonal antibody for the treatment of Parkinson's disease and other related synucleinopathies. Court Grants N50 Million Bail to Two MTN Employees Accused of N1.3 Billion Theft
All Africa Global Media - Thu Feb 27, 1:05AM CST
An Ikeja High Court on Wednesday granted bail to two MTN employees, Victor Akintunde and Gani Mustapha, charged with stealing N1.3 billion belonging to the firm's cooperative society.
Prothena to Report Fourth Quarter and Full Year 2013 Financial Results and Host Webcast and Conference Call on March 6
Thomson Reuters ONE - Tue Feb 18, 3:05PM CST
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
Prothena Announces Closing of Underwritten Public Offering of Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional Ordinary Shares From Perrigo
Thomson Reuters ONE - Mon Feb 03, 3:05PM CST
DUBLIN, Ireland, Feb. 3, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq
RTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding and cell adhesion, announced today the closing of a previously announced underwritten public offering of its ordinary shares owned by Elan Science One Limited (the "Selling Shareholder"), an indirect wholly owned subsidiary of Perrigo Company plc ("Perrigo"). The offering of 3,182,253 ordinary shares of Prothena included 415,076 ordinary shares that were sold pursuant to the underwriters' option to purchase additional shares, which was exercised in full prior to closing. The ordinary shares were sold at a price to the public of $26.00 per ordinary share, before the underwriting discount. As a result of the full exercise of the underwriters' option, the Selling Shareholder and Perrigo no longer own any ordinary shares of Prothena. 3 Big-Volume Biotech Stocks to Watch
at The Street - Thu Jan 30, 6:00AM CST
Keep these biotech stocks rising on unusual volume on your radar.
3 Companies Working on Parkinson's Treatments You Ought to Know About
Todd Campbell, The Motley Fool - Motley Fool - Wed Jan 29, 1:52PM CST
Parkinson's Disease effects between 7 million and 10 million patients worldwide. Roughly 60,000 new cases will be diagnosed in the United States this year alone, yet despite that big unmet need drug makers have stumbled in their attempts to bring...
Prothena Announces Pricing of Secondary Offering of Ordinary Shares by Perrigo
Thomson Reuters ONE - Wed Jan 29, 7:01AM CST
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
Prothena Corporation plc proposes secondary offering of 2.77m ordinary shares
M2 - Tue Jan 28, 3:48AM CST
Biotechnology company Prothena Corporation plc (NasdaqGS
RTA) said on Monday that it plans to offer an underwritten secondary public offering of 2,767,177 ordinary shares. Prothena Announces Proposed Secondary Offering of Ordinary Shares by Perrigo
Thomson Reuters ONE - Mon Jan 27, 3:26PM CST
DUBLIN, Ireland, Jan. 27, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq
RTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding and cell adhesion, announced today the underwritten public offering of 2,767,177 ordinary shares of Prothena by Elan Science One Limited (the "Selling Shareholder"), an indirect wholly owned subsidiary of Perrigo Company plc ("Perrigo"). In addition, the Selling Shareholder has granted the underwriters a 30-day option to purchase up to an additional 415,076 ordinary shares. Prothena to Receive $30 Million Upfront Payment from Roche Triggered by the Expiration of Hart-Scott-Rodino Waiting Period
Thomson Reuters ONE - Thu Jan 23, 7:00AM CST
DUBLIN, Ireland, Jan. 23, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq
RTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding and cell adhesion, announced today that, pursuant to its License, Development, and Commercialization Agreement with Roche, it will receive the $30 million upfront payment from Roche as a result of the License Agreement having become effective upon the expiration of the Hart-Scott-Rodino waiting period. Prothena to be Added to NASDAQ Biotechnology Index and NASDAQ Global Select Market
Thomson Reuters ONE - Mon Dec 30, 7:00AM CST
DUBLIN, Ireland, Dec. 30, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq
RTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of a broad range of diseases, today announced that it was selected for addition to the NASDAQ Biotechnology Index (Nasdaq:NBI), which became effective before market open on December 23, 2013. Prothena also announced that its common stock will be transferred to the NASDAQ Global Select Market effective January 2, 2014. 
